Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated Steatohepatitis.
作者信息
Chalasani Naga
机构信息
Vice President for Academic Affairs, Indiana University Health David W. Crabb Professor of Gastroenterology and Hepatology Adjunct Professor of Anatomy, Cell Biology and Physiology Indiana University School of Medicine Indianapolis, Indiana.
出版信息
Gastroenterol Hepatol (N Y). 2024 Aug;20(8):460-503.
Abstract
摘要
相似文献
1
Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎的遗传学现状与多基因风险评分
Gastroenterol Hepatol (N Y). 2024 Aug;20(8):460-503.
2
Polygenic risk scores: from research tools to clinical instruments.多基因风险评分：从研究工具到临床工具。
Genome Med. 2020 May 18;12(1):44. doi: 10.1186/s13073-020-00742-5.
3
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.部署与代谢功能障碍相关的脂肪性肝炎共识护理路径：三项卫生系统教育试点的结果。
BMC Prim Care. 2024 Jul 20;25(1):265. doi: 10.1186/s12875-024-02517-y.
4
Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study.精神分裂症多基因风险对心脏结构和功能的影响：一项英国生物银行观察性研究。
Lancet Psychiatry. 2023 Feb;10(2):98-107. doi: 10.1016/S2215-0366(22)00403-5. Epub 2023 Jan 8.
5
Systematic Review of Polygenic Risk Scores for Type 1 and Type 2 Diabetes.1 型和 2 型糖尿病多基因风险评分的系统评价。
Int J Mol Sci. 2020 Mar 2;21(5):1703. doi: 10.3390/ijms21051703.
6
A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond .对评估阿尔茨海默病病理学及其他方面多基因负担的方法进行全面分析。 （注：原文“beyond”后内容缺失，此译文根据现有内容尽量完善）
Brain Commun. 2020;2(1):fcz047. doi: 10.1093/braincomms/fcz047. Epub 2019 Dec 16.
7
Polygenic risk scores in imaging genetics: Usefulness and applications.影像遗传学中的多基因风险评分：实用性与应用
J Psychopharmacol. 2015 Aug;29(8):867-71. doi: 10.1177/0269881115584470. Epub 2015 May 5.
8
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.代谢功能障碍相关脂肪性肝病增加慢性乙型肝炎患者不良结局的风险。
JHEP Rep. 2021 Aug 8;3(5):100350. doi: 10.1016/j.jhepr.2021.100350. eCollection 2021 Oct.
9
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.基于性别的差异，自然杀伤 T 细胞在保护 Balb/c 小鼠抵抗饮食诱导的脂肪性肝炎中的作用。
Biol Sex Differ. 2023 Nov 14;14(1):85. doi: 10.1186/s13293-023-00569-w.
10
Major depressive disorder and current psychological distress moderate the effect of polygenic risk for obesity on body mass index.重度抑郁症和当前的心理困扰会缓和肥胖多基因风险对体重指数的影响。
Transl Psychiatry. 2015 Jun 30;5(6):e592. doi: 10.1038/tp.2015.83.
本文引用的文献
1
Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation.低MBOAT7表达是MASH的遗传风险，它促进了一条涉及肝细胞TAZ上调的促纤维化途径。
Hepatology. 2025 Feb 1;81(2):576-590. doi: 10.1097/HEP.0000000000000933. Epub 2024 May 22.
2
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.载脂蛋白 L3(rs738409)、年龄、糖尿病、性别和肝纤维化程度共同导致代谢相关脂肪性肝病伴显著肝纤维化患者发生主要不良肝脏结局的风险增加。
Hepatology. 2024 Nov 1;80(5):1212-1226. doi: 10.1097/HEP.0000000000000896. Epub 2024 Apr 23.
3
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.年龄、BMI 和 2 型糖尿病改变了 PNPLA3 与儿童和成人非酒精性脂肪性肝病患者肝纤维化程度的关系。
Clin Gastroenterol Hepatol. 2024 May;22(5):1024-1036.e2. doi: 10.1016/j.cgh.2023.12.009. Epub 2023 Dec 23.
4
Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease.全基因组关联荟萃分析确定了 17 个与非酒精性脂肪性肝病相关的位点。
Nat Genet. 2023 Oct;55(10):1640-1650. doi: 10.1038/s41588-023-01497-6. Epub 2023 Sep 14.
5
Therapeutic opportunities for the treatment of NASH with genetically validated targets.治疗 NASH 的治疗机会与基因验证的靶点。
J Hepatol. 2023 Oct;79(4):1056-1064. doi: 10.1016/j.jhep.2023.05.007. Epub 2023 May 17.
6
Advances in the genetics of nonalcoholic fatty liver disease.非酒精性脂肪性肝病遗传学研究进展。
Curr Opin Gastroenterol. 2023 May 1;39(3):150-155. doi: 10.1097/MOG.0000000000000927. Epub 2023 Mar 1.
7
Clinical utility of polygenic risk scores for predicting NAFLD disorders.多基因风险评分预测非酒精性脂肪性肝病相关疾病的临床效用。
J Hepatol. 2021 Apr;74(4):769-770. doi: 10.1016/j.jhep.2021.02.005. Epub 2021 Feb 27.
Zotero 插件